Dechra reports strong growth in latest fiscal quarter

Dechra has published its interim management statement for the fiscal quarter running from July to October 2012, highlighting a strong performance that was in line with internal expectations.

Revenue growth during the first three months of the company's 2012/13 business year was 21.9 percent, or six percent when factoring out the significant positive impact of the recent Eurovet acquisition.

European pharmaceutical sales increased by 3.2 percent year over year and US revenues experienced a 24.8 percent rise, while the integration of Eurovet is proceeding as planned.

Additionally, the firm announced a number of changes to its board, including the departure of group finance director Simon Evans and the appointment of Tony Griffin as a director on November 1st 2012.

The company's summary of its fiscal performance stated: "The group has made an excellent start to the year and its financial position remains strong."

Earlier this month, Dechra announced the retirement of Bob Hartley, its territory manager for the south-west of England, following a career in the animal health industry spanning more than four decades.